Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: A meta-analysis

Sana M. Al-Khatib, Gregg C. Fonarow, Jose A. Joglar, Lurdes Y.T. Inoue, Daniel B. Mark, Kerry L. Lee, Alan Kadish, Gust Bardy, Gillian D. Sanders

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Importance: Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. Objective: To investigate the association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiomyopathy. Data Sources: PubMed was searched from January 1, 2000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy. Additional references were identified from bibliographies of pertinent articles and queries to experts in this field. Study Selection: Inclusion criteria consisted of a randomized clinical trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with nonischemic cardiomyopathy. In addition, studies had to report on all-cause mortality during a follow-up period of at least 12 months and be published in English. The search yielded 10 studies, of which only 1met the inclusion criteria. A search of bibliographies of pertinent articles and queries of experts in this field led to 3 additional studies. Data Extraction and Synthesis: The PRISMA guidelines were used to abstract data and assess data quality and validity. Data were pooled using fixed- and random-effects models. Main Outcomes and Measures: The primary end pointwas all-cause mortality. Before data collection started, primary prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic cardiomyopathy. Results: Four randomized clinical trials met the selection criteria and included 1874 unique patients; 937 were in the ICD group and 937 in the control group. Pooling data from these trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95% CI, 0.61-0.93; P = .008; P = .87 for heterogeneity). Conclusions and Relevance: Primary prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic cardiomyopathy. These findings support professional guidelines that recommend the use of ICDs in such patients.

Original languageEnglish (US)
Pages (from-to)685-688
Number of pages4
JournalJAMA Cardiology
Volume2
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Implantable Defibrillators
Primary Prevention
Cardiomyopathies
Meta-Analysis
Mortality
Sudden Cardiac Death
Bibliography
Patient Selection
Randomized Controlled Trials
Guidelines
Information Storage and Retrieval
PubMed
Outcome Assessment (Health Care)
Control Groups

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy : A meta-analysis. / Al-Khatib, Sana M.; Fonarow, Gregg C.; Joglar, Jose A.; Inoue, Lurdes Y.T.; Mark, Daniel B.; Lee, Kerry L.; Kadish, Alan; Bardy, Gust; Sanders, Gillian D.

In: JAMA Cardiology, Vol. 2, No. 6, 01.06.2017, p. 685-688.

Research output: Contribution to journalArticle

Al-Khatib, SM, Fonarow, GC, Joglar, JA, Inoue, LYT, Mark, DB, Lee, KL, Kadish, A, Bardy, G & Sanders, GD 2017, 'Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: A meta-analysis', JAMA Cardiology, vol. 2, no. 6, pp. 685-688. https://doi.org/10.1001/jamacardio.2017.0630
Al-Khatib, Sana M. ; Fonarow, Gregg C. ; Joglar, Jose A. ; Inoue, Lurdes Y.T. ; Mark, Daniel B. ; Lee, Kerry L. ; Kadish, Alan ; Bardy, Gust ; Sanders, Gillian D. / Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy : A meta-analysis. In: JAMA Cardiology. 2017 ; Vol. 2, No. 6. pp. 685-688.
@article{ee6e6bf8f8cf4b8980541bab748c5d92,
title = "Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: A meta-analysis",
abstract = "Importance: Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. Objective: To investigate the association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiomyopathy. Data Sources: PubMed was searched from January 1, 2000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy. Additional references were identified from bibliographies of pertinent articles and queries to experts in this field. Study Selection: Inclusion criteria consisted of a randomized clinical trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with nonischemic cardiomyopathy. In addition, studies had to report on all-cause mortality during a follow-up period of at least 12 months and be published in English. The search yielded 10 studies, of which only 1met the inclusion criteria. A search of bibliographies of pertinent articles and queries of experts in this field led to 3 additional studies. Data Extraction and Synthesis: The PRISMA guidelines were used to abstract data and assess data quality and validity. Data were pooled using fixed- and random-effects models. Main Outcomes and Measures: The primary end pointwas all-cause mortality. Before data collection started, primary prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic cardiomyopathy. Results: Four randomized clinical trials met the selection criteria and included 1874 unique patients; 937 were in the ICD group and 937 in the control group. Pooling data from these trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95{\%} CI, 0.61-0.93; P = .008; P = .87 for heterogeneity). Conclusions and Relevance: Primary prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic cardiomyopathy. These findings support professional guidelines that recommend the use of ICDs in such patients.",
author = "Al-Khatib, {Sana M.} and Fonarow, {Gregg C.} and Joglar, {Jose A.} and Inoue, {Lurdes Y.T.} and Mark, {Daniel B.} and Lee, {Kerry L.} and Alan Kadish and Gust Bardy and Sanders, {Gillian D.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1001/jamacardio.2017.0630",
language = "English (US)",
volume = "2",
pages = "685--688",
journal = "JAMA Cardiology",
issn = "2380-6583",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy

T2 - A meta-analysis

AU - Al-Khatib, Sana M.

AU - Fonarow, Gregg C.

AU - Joglar, Jose A.

AU - Inoue, Lurdes Y.T.

AU - Mark, Daniel B.

AU - Lee, Kerry L.

AU - Kadish, Alan

AU - Bardy, Gust

AU - Sanders, Gillian D.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Importance: Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. Objective: To investigate the association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiomyopathy. Data Sources: PubMed was searched from January 1, 2000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy. Additional references were identified from bibliographies of pertinent articles and queries to experts in this field. Study Selection: Inclusion criteria consisted of a randomized clinical trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with nonischemic cardiomyopathy. In addition, studies had to report on all-cause mortality during a follow-up period of at least 12 months and be published in English. The search yielded 10 studies, of which only 1met the inclusion criteria. A search of bibliographies of pertinent articles and queries of experts in this field led to 3 additional studies. Data Extraction and Synthesis: The PRISMA guidelines were used to abstract data and assess data quality and validity. Data were pooled using fixed- and random-effects models. Main Outcomes and Measures: The primary end pointwas all-cause mortality. Before data collection started, primary prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic cardiomyopathy. Results: Four randomized clinical trials met the selection criteria and included 1874 unique patients; 937 were in the ICD group and 937 in the control group. Pooling data from these trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95% CI, 0.61-0.93; P = .008; P = .87 for heterogeneity). Conclusions and Relevance: Primary prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic cardiomyopathy. These findings support professional guidelines that recommend the use of ICDs in such patients.

AB - Importance: Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. Objective: To investigate the association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiomyopathy. Data Sources: PubMed was searched from January 1, 2000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy. Additional references were identified from bibliographies of pertinent articles and queries to experts in this field. Study Selection: Inclusion criteria consisted of a randomized clinical trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with nonischemic cardiomyopathy. In addition, studies had to report on all-cause mortality during a follow-up period of at least 12 months and be published in English. The search yielded 10 studies, of which only 1met the inclusion criteria. A search of bibliographies of pertinent articles and queries of experts in this field led to 3 additional studies. Data Extraction and Synthesis: The PRISMA guidelines were used to abstract data and assess data quality and validity. Data were pooled using fixed- and random-effects models. Main Outcomes and Measures: The primary end pointwas all-cause mortality. Before data collection started, primary prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic cardiomyopathy. Results: Four randomized clinical trials met the selection criteria and included 1874 unique patients; 937 were in the ICD group and 937 in the control group. Pooling data from these trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95% CI, 0.61-0.93; P = .008; P = .87 for heterogeneity). Conclusions and Relevance: Primary prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic cardiomyopathy. These findings support professional guidelines that recommend the use of ICDs in such patients.

UR - http://www.scopus.com/inward/record.url?scp=85026447143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026447143&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2017.0630

DO - 10.1001/jamacardio.2017.0630

M3 - Article

C2 - 28355432

AN - SCOPUS:85026447143

VL - 2

SP - 685

EP - 688

JO - JAMA Cardiology

JF - JAMA Cardiology

SN - 2380-6583

IS - 6

ER -